{"entity":{"id":"biodexa-pharmaceuticals","kind":"company","name":"Biodexa Pharmaceuticals","aka":["Biodexa Pharmaceuticals PLC"],"tldr":"Biodexa Pharmaceuticals is a Cardiff company developing eRapa, a new form of the drug rapamycin, in a large trial for an inherited condition that causes bowel polyps and cancer, and MTX240, an early drug for gastrointestinal stromal tumour.","summary":"Biodexa Pharmaceuticals PLC, of Cardiff, describes a pipeline for gastrointestinal stromal tumour (GIST), familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer and type 1 diabetes. In April 2024 it licensed eRapa, an encapsulated formulation of the mTOR inhibitor rapamycin, from Emtora Biosciences. A registrational phase 3 trial of eRapa in FAP, 168 patients randomised 2:1 against placebo at about 30 sites in the United States and Europe and funded largely by grants from the Cancer Prevention and Research Institute of Texas, passed the half-way point of recruitment in August 2026; a phase 2 investigator-initiated trial in non-muscle invasive bladder cancer is run by the University of Texas, San Antonio. In February 2026 it licensed MTX240 from Otsuka, a molecular glue for GIST.","asOf":"2026-11-04","links":[{"label":"SEC: Biodexa Pharmaceuticals Form F-1, September 2026","url":"https://www.sec.gov/Archives/edgar/data/1643918/000121465926011934/y917262f1.htm"},{"label":"Official website","url":"https://www.biodexapharma.com/"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","prevention"],"technologies":[],"targets":["mtor","kit"],"drugs":["erapa","mtx240"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 4 November 2026 in the F-1 filed with the SEC on 24 September 2026. The filing reports FDA fast track designation for eRapa in February 2025 without naming the indication in the passage read, so no dated designation is recorded. Trial registry numbers are not given in the passage read."],"hq":"Cardiff","country":"GB","companyType":"biotech","website":"https://www.biodexapharma.com/","ticker":"BDRX","stage":"public","investors":[],"funding":[]},"route":"/companies/biodexa-pharmaceuticals/","neighbours":{"section":[{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/"}],"drug":[{"id":"erapa","kind":"drug","name":"eRapa","route":"/drugs/erapa/"},{"id":"mtx240","kind":"drug","name":"MTX240","route":"/drugs/mtx240/"}]}}